British drugmaker AstraZeneca (LSE: AZN) has sold the remaining rights to its anesthetics division to Aspen Pharma (JSE: APN), a South African firm with a $10 billion market cap.
Under the terms of a June 2016 agreement AstraZeneca sold the exclusive commercialization rights to the medicines in markets outside the USA. Now, Aspen will acquire remaining IP and manufacturing rights for $555 million.
The deal relates to the established products EMLA (lidocaine and prilocaine), Xylocaine/Xylocard/Xyloproct (lidocaine hydrochloride), Marcaine (bupivacaine hydrochloride), Naropin (ropivacaine hydrochloride), Carbocaine (mepivacaine) and Citanest (prilocaine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze